TQB3823 / Sino Biopharm - LARVOL DELTA

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=39 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=78 ➔ 39 | Trial completion date: Apr 2024 ➔ Jul 2023 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2024 ➔ Jul 2023; The sponsor voluntarily terminated the study

Enrollment change • Metastases • Trial completion date • Trial primary completion date • Trial termination • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - P1 | N=164 | Active, not recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting ➔ Active, not recruiting | N=64 ➔ 164 | Trial completion date: Oct 2022 ➔ Oct 2025 | Trial primary completion date: Mar 2022 ➔ Feb 2025

Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov) - P1/2 | N=78 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

New P1/2 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Clinical Study of TQB3823 in Patients With Advanced Malignant Tumor (clinicaltrials.gov) - P1; N=64; Recruiting; Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial • Oncology • Solid Tumor

[VIRTUAL] Characterization of TQB3823, a differentiated PARP inhibitor with anti-tumor activity in BRCA-deficiency cancer models (AACR 2021) - "The level of antitumor effects was superior to niraparib at the same dose in the same study. DNA trapping experiments revealed similar potency to olaparib indicative of low toxicity. We have identified a novel, potent and selective PARP inhibitor TQB3823, which inhibits the proliferation of BRCA mutant cells but spares the wild type cells. We have identified a novel, potent and selective PARP inhibitor TQB3823, which inhibits the proliferation of BRCA mutant cells but spares the wild type cells. In vivo study in a BRCA-deficiency tumor model confirms the high in vivo efficacy of this molecule. In conclusion, TQB3823 represents a promising differentiated clinical candidate for treating solid cancers with homology directed repair."

Preclinical • Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • PARP2